Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults

The oncogenic mechanisms underlying acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA; 15–39 years old) remain largely elusive. Here we have searched for new oncogenes in AYA-ALL by performing RNA-seq analysis of Philadelphia chromosome (Ph)-negative AYA-ALL specimens (n = 73) with the use of a next-generation sequencer. Interestingly, insertion of D4Z4 repeats containing the DUX4 gene into the IGH locus was frequently identified in B cell AYA-ALL, leading to a high level of expression of DUX4 protein with an aberrant C terminus. A transplantation assay in mice demonstrated that expression of DUX4-IGH in pro-B cells was capable of generating B cell leukemia in vivo. DUX4 fusions were preferentially detected in the AYA generation. Our data thus show that DUX4 can become an oncogenic driver as a result of somatic chromosomal rearrangements and that AYA-ALL may be a clinical entity distinct from ALL at other ages.

[1]  H. Sakamoto,et al.  A novel recurrent EP300–ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia , 2015, Leukemia.

[2]  Süleyman Cenk Sahinalp,et al.  deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data , 2011, PLoS Comput. Biol..

[3]  H. Kantarjian,et al.  Acute lymphoblastic leukemia in adolescents and young adults , 2017, Cancer.

[4]  C. Harrison Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia , 2009, British journal of haematology.

[5]  W. Wood,et al.  Malignant hematologic diseases in adolescents and young adults. , 2011, Blood.

[6]  R. Wade,et al.  IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Rosa,et al.  Multiple Protein Domains Contribute to Nuclear Import and Cell Toxicity of DUX4, a Candidate Pathogenic Protein for Facioscapulohumeral Muscular Dystrophy , 2013, PloS one.

[8]  P. Marynen,et al.  Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia. , 2002, Cancer research.

[9]  Thomas Ragg,et al.  The RIN: an RNA integrity number for assigning integrity values to RNA measurements , 2006, BMC Molecular Biology.

[10]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[11]  J. Inazawa,et al.  Identification of a novel fusion gene in a pre‐B acute lymphoblastic leukemia with t(1;19)(q23;p13) , 2004, Cancer science.

[12]  H. Aburatani,et al.  Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. , 2006, Human molecular genetics.

[13]  A. Rosa,et al.  The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein , 2007, Neuromuscular Disorders.

[14]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[15]  T. Naoe,et al.  Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group , 2014, Blood Cancer Journal.

[16]  D. Gabellini,et al.  FSHD: copy number variations on the theme of muscular dystrophy , 2010, The Journal of cell biology.

[17]  S. Tsuzuki,et al.  TEL (ETV6)‐AML1 (RUNX1) Initiates Self‐Renewing Fetal Pro‐B Cells in Association with a Transcriptional Program Shared with Embryonic Stem Cells in Mice , 2013, Stem cells.

[18]  C. Wijmenga,et al.  Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy , 1992, Nature genetics.

[19]  P. Marynen,et al.  Cellular transformation of NIH3T3 fibroblasts by CIZ/NMP4 fusions , 2005, Journal of cellular biochemistry.

[20]  O. King,et al.  Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. , 2012, Human molecular genetics.

[21]  S. Hunger,et al.  Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia , 2007, Leukemia.

[22]  D. Roth Restraining the V(D)J recombinase , 2003, Nature Reviews Immunology.

[23]  J. Hewitt,et al.  Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. , 2007, American journal of human genetics.

[24]  H. Qian,et al.  DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1 , 2007, Proceedings of the National Academy of Sciences.

[25]  Abraham P. Fong,et al.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. , 2012, Developmental cell.

[26]  Daniel G. Miller,et al.  Facioscapulohumeral Dystrophy: Incomplete Suppression of a Retrotransposed Gene , 2010, PLoS genetics.